Tesamorelin – 5mg

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH) consisting of the full 44 amino acid native GHRH sequence with a trans 3 hexenoic acid modification that significantly extends its plasma half-life compared to native GHRH. One of the few GHRH analogues to achieve full FDA approval, cleared for the treatment of HIV associated lipodystrophy under the brand name Egrifta. iLab Pharma’s 5mg lyophilized vial delivers a lower concentration presentation than the Hudson Science 20mg Tesamorelin vial; suited to researchers initiating Tesamorelin protocols, conducting initial dose response characterization, or requiring a supply volume matched to shorter duration research timelines before committing to larger vial concentrations.

The 5mg and 20mg Tesamorelin vials serve distinct research procurement purposes within CSD’s Tesamorelin range. The 5mg iLab Pharma format provides the lowest standalone concentration entry point; suited to protocols beginning at conservative GHRH receptor activation levels, initial compound evaluation before progressing to the 20mg Hudson Science vial for extended protocols, or research designs where precise low dose reconstitution concentration control is the priority variable. Both presentations deliver the same Tesamorelin pharmacological profile, trans 3 hexenoic acid stabilized full sequence GHRH receptor agonism producing physiologically regulated pulsatile GH secretion with concentration and manufacturer representing the sole differentiating variables.

CSD stocks three distinct GHRH receptor agonists covering the full half-life and clinical documentation spectrum. Sermorelin’s 29 amino acid truncated sequence with the shortest active window and most adjustable clearance profile, Tesamorelin’s full 44 amino acid trans 3 hexenoic acid stabilized sequence with FDA approval underpinning its clinical literature, and CJC-1295’s DAC modified albumin bound profile producing the longest active window at 6–8 days. Tesamorelin occupies the intermediate position. Its longer acting than Sermorelin with established clinical approval documentation, shorter acting than CJC-1295 with DAC without the albumin binding modification’s continuous baseline elevation profile. All three are available from a single verified Canadian supplier for complete GHRH analogue half-life spectrum research coverage.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s Tesamorelin meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside CJC-1295 and Ipamorelin in comparative GHRH axis stimulation and GH secretagogue studies. Browse CSD’s full peptide range for complete sourcing.